BRAF and ovarian carcinoma: We then used Idylla in a retrospective study to test FFPE tumor samples from 100 patients with advanced cancers (melanoma, n = 38; colorectal cancer, n = 25; papillary thyroid carcinoma, n = 12; ovarian cancer, n = 5; cholangiocarcinoma, n = 3; head and neck cancer, n = 3; gastrointestinal stromal tumor, n = 2; NSCLC, n = 2; other, n = 10, Table 4) whose BRAF V600 mutation status had been previously determined in MD Anderson's Clinical Laboratory Improvement Amendments (CLIA)-certified Molecular Diagnostics Laboratory from routine clinical biopsies and resections.